Opioid prescribing prevalence and initiation rates in Victoria, Australia: insights from primary care data during a period of opioid policy changes (2017-2022)

被引:2
作者
Balikci, Zeynep [1 ,2 ]
Kondratova, Ulyana [1 ,3 ]
Picco, Louisa [1 ]
Nielsen, Suzanne [1 ]
Xia, Ting [1 ]
机构
[1] Monash Univ, Monash Addict Res Ctr, Eastern Hlth Clin Sch, Level 2 Bldg D, 47-49 Moorooduc Highway, Melbourne, Vic 3199, Australia
[2] Monash Univ, Sch Biomed Sci, Melbourne, Australia
[3] Monash Univ, Sch Med, Melbourne, Australia
基金
英国医学研究理事会;
关键词
General practice; Health policy; Opioids; Prescribing; Primary care; PAIN; CONSUMPTION; SEX;
D O I
10.1007/s11096-024-01849-0
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
BackgroundOpioid medications are widely prescribed for acute, chronic and cancer pain. In Australia, opioid prescribing rates remain high.AimThis study aimed to document patterns of primary care opioid prescribing from 2017 to 2022 by demographic characteristics in Victoria, Australia.MethodThis study was a retrospective descriptive analysis, examining prescribing data sourced from the population level analysis and reporting general practice analytics platform. We examined monthly opioid prescription and initiation rates across diverse demographic factors such as age, gender, socioeconomic status (SES), and geographical location. Poisson regression was used to calculate rate ratios for the incidence of opioid initiation over time, adjusting for age, gender, and SES.ResultsBetween 2017 and 2022, tapentadol prescriptions increased by 263%, while prescription rates for other opioids declined. Females accounted for 53% of opioid prescriptions, but males had higher initiation rates. Initiation rates declined across most demographics, except for the 15-24 age group, which experienced a 69% increase. Socioeconomically disadvantaged and regional/remote populations showed higher prescribing rates but significant declines over time.ConclusionThis study contributes valuable insights into the prescribing trends in primary health settings. The findings suggest targeted interventions to address socioeconomic and regional disparities are needed, to ensure the quality use of opioids across diverse populations.
引用
收藏
页码:443 / 451
页数:9
相关论文
共 41 条
[1]  
Ju C., Wei L., Man K.K., Et al., Global, regional, and national trends in opioid analgesic consumption from 2015 to 2019: a longitudinal study, Lancet Public Health, 7, 4, pp. e335-e346, (2022)
[2]  
World Drug Report 2023. ONODC, (2023)
[3]  
. Penington Institute Melbourne, (2022)
[4]  
Therapeutic Goods Administration. Prescription Opioids: What Changes are Being Made and Why? Available From, (2021)
[5]  
Roberts D.M., Nielsen S., Changes for codeine, Aust Prescr, 41, 1, pp. 2-3, (2018)
[6]  
Australian Government, Editor. Canberra, (2022)
[7]  
Verhamme K.M., Bohnen A.M., Are we facing an opioid crisis in Europe?, Lancet Public Health, 4, 10, pp. e483-e484, (2019)
[8]  
Busingye D., Daniels B., Brett J., Et al., Patterns of real-world opioid prescribing in Australian general practice (2013–18), Aust J Prim Health, 27, 5, pp. 416-424, (2021)
[9]  
Reid S., Day C., White N., Et al., Opioid prescribing in general practice: an Australian cross-sectional survey, BMC Prim Care, 23, 1, (2022)
[10]  
Lalic S., Ilomaki J., Bell J.S., Et al., Prevalence and incidence of prescription opioid analgesic use in Australia, Br J Clin Pharmacol, 85, 1, pp. 202-215, (2019)